SCHEMBL1482178

SCHEMBL1482178

CCn1cc(-c2ccccc2OC)nc1/C=C/c1ccc(Br)cc1

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TLR8 Q9NR97 2/20 0.45
HDAC1 Q13547 2/20 0.40
HDAC6 Q9UBN7 2/20 0.40
KDM1A O60341 1/20 0.40
TUBB4A P04350 1/20 0.39
TUBB P07437 1/20 0.39
TUBA3C P0DPH7 1/20 0.39
TUBA1B P68363 1/20 0.39
TUBA4A P68366 1/20 0.39
TUBB4B P68371 1/20 0.39
TUBB3 Q13509 1/20 0.39
TUBB2A Q13885 1/20 0.39
TUBB8 Q3ZCM7 1/20 0.39
TUBA3E Q6PEY2 1/20 0.39
TUBA1A Q71U36 1/20 0.39
TUBA1C Q9BQE3 1/20 0.39
TUBB6 Q9BUF5 1/20 0.39
TUBB2B Q9BVA1 1/20 0.39
TUBB1 Q9H4B7 1/20 0.39
RAB9A P51151 5/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1482180 1.00 TLR8 (0.45) TLR8HDAC1HDAC6KDM1ATUBB4A
SCHEMBL1481749 0.86 MEN1 (0.44) TLR8HDAC1HDAC6KDM1ARAB9A
SCHEMBL1481745 0.86 MEN1 (0.44) TLR8HDAC1HDAC6KDM1ARAB9A
SCHEMBL1481852 0.84 TLR8 (0.43) TLR8RAB9ASMN1; SMN2NPC1TP53
SCHEMBL1481849 0.84 TLR8 (0.43) TLR8RAB9ASMN1; SMN2NPC1TP53
SCHEMBL6452095 0.80 BRS3 (0.41) TLR8HDAC1HDAC6RAB9ASMN1; SMN2
SCHEMBL1481511 0.79 TLR8 (0.44) TLR8HDAC1HDAC6KDM1ARAB9A
SCHEMBL6529127 0.79 TLR8 (0.44) TLR8HDAC1HDAC6KDM1ARAB9A
SCHEMBL6529126 0.79 TLR8 (0.44) TLR8HDAC1HDAC6KDM1ARAB9A
SCHEMBL1481515 0.79 TLR8 (0.44) TLR8HDAC1HDAC6KDM1ARAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110077399-A1 Substituted Azole Derivatives as Therapeutic Agents TRANSTECH PHARMA, INC. (US) 2011-03-31 US disclosed
US-20040192743-A1 Substituted azole derivatives as therapeutic agents TRANSTECH PHARMA, INC. 2004-09-30 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040192743-A1 Substituted azole derivatives as therapeutic agents PTPRS, PTPRO, PTPRJ TLR8 2695/4885HDAC1 1874/4885HDAC6 1595/4885
US-20110077399-A1 Substituted Azole Derivatives as Therapeutic Agents PTPRS, PTPRO, PTPRJ TLR8 2695/4885HDAC1 1874/4885HDAC6 1595/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.